- Home
- SGMT vs WLAC Comparison
SGMT vs WLAC Comparison
Compare SGMT & WLAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SGMT | WLAC |
|---|---|---|
| Founded | 2006 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.4M | 184.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SGMT | WLAC |
|---|---|---|
| Price | $4.90 | $10.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $26.38 | $17.00 |
| AVG Volume (30 Days) | ★ 321.0K | 184.6K |
| Earning Date | 03-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $784.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.73 | $10.02 |
| 52 Week High | $11.41 | $15.19 |
Technical Indicators
Market Signals| Indicator | SGMT | WLAC |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 40.53 |
| Support Level | N/A | $10.25 |
| Resistance Level | $6.62 | $11.22 |
| Average True Range (ATR) | 0.29 | 0.23 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 25.74 | 24.59 |
Price Performance
Historical ComparisonAbout SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About WLAC Willow Lane Acquisition Corp. Class A Ordinary Shares
Willow Lane Acquisition Corp is a blank check company.